Background/Aims: This study investigated the effect of Helicobacter pylori eradication therapy on latent digestive symptoms in chronic atrophic gastritis. Methods: We enrolled 650 health checkup patients who underwent eradication therapy for chronic gastritis and completed a self-report questionnaire before and after the treatment between January 2014 and December 2016 at the Japanese Red Cross Society Kyoto Daiichi Hospital. Results:H. pylori eradication therapy for chronic atrophic gastritis improved latent digestive symptoms, including both the acid reflux and dyspepsia components in the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) scores. The effect was sustained until 1 year after the treatment. Higher FSSG scores (≥8 points) before H. pylori eradication therapy and age <70 years were significantly associated with the improvement of digestive symptoms after H. pylori eradication therapy. Conclusion:H. pylori eradication therapy may improve patients’ quality of life through the resolution of latent abdominal symptoms.

Journal Section:
Original Paper
Keywords:
H. pylori eradication therapy, Latent digestive symptoms, Gastrointestinal Symptom Rating Scale
1.
Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; 2:CD002096.
2.
Du LJ, Chen BR, Kim JJ, Kim S, Shen JH, Dai N: Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis. World J Gastroenterol 2016; 22: 3486–3495.
3.
Moayyedi P: Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on “Helicobacter pylori eradication in functional dyspepsia”. Arch Intern Med 2011; 171: 1936–1937.
4.
Miwa H, Kusano M, Arisawa T, Oshima T, Kato M, Joh T, Suzuki H, Tominaga K, Nakada K, Nagahara A, Futagami S, Manabe N, Inui A, Haruma K, Higuchi K, Yakabi K, Hongo M, Uemura N, Kinoshita Y, Sugano K, Shimosegawa T; Japanese Society of Gastroenterology: Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol 2015; 50: 125–139.
5.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group: Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646–664.
6.
Raghunath AS, Hungin AP, Wooff D, Childs S: Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004; 20: 733–744.
7.
Xie T, Cui X, Zheng H, Chen D, He L, Jiang B: Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2013; 25: 1195–1205.
8.
Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH: Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol 2010; 105: 1007–1013; quiz 1006, 1014.
9.
Sugimoto M, Uotani T, Ichikawa H, Andoh A, Furuta T: Gastroesophageal reflux disease in time covering eradication for all patients infected with Helicobacter pylori in Japan. Digestion 2016; 93: 24–31.
10.
Kusano M, Hosaka H, Kawada A, Kuribayashi S, Shimoyama Y, Kawamura O, Moki F: Development and evaluation of a modified Frequency Scale for the symptoms of gastroesophageal reflux disease to distinguish functional dyspepsia from non-erosive reflux disease. J Gastroenterol Hepatol 2012; 27: 1187–1191.
11.
Svedlund J, Sjödin I, Dotevall G: GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129–134.
12.
McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, Kelman A, Penny C, Knill-Jones R, Hilditch T: Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer ­dyspepsia. N Engl J Med 1998; 339: 1869–1874.
13.
Blum AL, Talley NJ, O’Moráin C, van Zanten SV, Labenz J, Stolte M, Louw JA, Stubberöd A, Theodórs A, Sundin M, ­Bolling-Sternevald E, Junghard O: Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998; 339: 1875–1881.
14.
Talley NJ, Janssens J, Lauritsen K, Rácz I, Bolling-Sternevald E: Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 1999; 318: 833–837.
15.
Suzuki H, Masaoka T, Sakai G, Ishii H, Hibi T: Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol 2005; 20: 1652–1660.
16.
Miwa H, Hirai S, Nagahara A, Murai T, Nishira T, Kikuchi S, Takei Y, Watanabe S, Sato N: Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000; 14: 317–324.
17.
Kamada T, Haruma K, Hata J, Kusunoki H, Sasaki A, Ito M, Tanaka S, Yoshihara M: The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther 2003; 18: 245–252.
18.
Fallone CA, Barkun AN, Friedman G, Mayrand S, Loo V, Beech R, Best L, Joseph L: Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000; 95: 914–920.
19.
Befrits R, Sjöstedt S, Odman B, Sörngård H, Lindberg G: Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter 2000; 5: 202–205.
20.
Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT: Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120–1126.
21.
Laine L, Dhir V: Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Aliment Pharmacol Ther 2002; 16: 1143–1148.
22.
Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P; Bristol Helicobacter Project: Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. BMJ 2004; 328: 1417.
23.
Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, Festen HP, Dent J, Zeitoun P, Havu N, Lamm M, Walan A: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 12–20.
24.
Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R, Chung SC, Sung JJ: Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004; 53: 174–179.
25.
Mori H, Suzuki H, Matsuzaki J, Taniguchi K, Shimizu T, Yamane T, Masaoka T, Kanai T. Gender difference of gastric emptying in healthy volunteers and patients with functional dyspepsia. Digestion 2017; 95: 72–78.
26.
Takeshita E, Sakata Y, Hara M, Akutagawa K, Sakata N, Endo H, Ohyama T, Matsunaga K, Yoshioka T, Kawakubo H, Tanaka Y, Shirai S, Ito Y, Tsuruoka N, Iwakiri R, Kusano M, Fujimoto K: Higher frequency of reflux symptoms and acid-related dyspepsia in women than men regardless of endoscopic esophagitis: analysis of 3,505 Japanese subjects undergoing medical health checkups. Digestion 2016; 93: 266–271.
27.
Dwivedi M, Misra SP, Misra V: Nodular gastritis in adults: clinical features, endoscopic appearance, histopathological features, and response to therapy. J Gastroenterol Hepatol 2008; 23: 943–947.
28.
Shiotani A, Kamada T, Kumamoto M, Nakae Y, Nakamura Y, Kakudo K, Haruma K: Nodular gastritis in Japanese young adults: endoscopic and histological observations. J Gastroenterol 2007; 42: 610–615.
29.
Yoshida N: Inflammation and oxidative stress in gastroesophageal reflux disease. J Clin Biochem Nutr 2007; 40: 13–23.
30.
Yoshida N, Kuroda M, Suzuki T, Kamada K, Uchiyama K, Handa O, Takagi T, Yoshikawa T, Kuramoto H: Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig Dis Sci 2013; 58: 2237–2243.
31.
Erin N, Türker S, Elpek O, Yıldırım B: Differential changes in Substance P, VIP as well as neprilysin levels in patients with gastritis or ulcer. Peptides 2012; 35: 218–224.
32.
Choi YJ, Kim N, Yoon H, Shin CM, Park YS, Park JH, Nam RH, Lee DH, Jung HC: Increase in plasma acyl ghrelin levels is associated with abatement of dyspepsia following Helicobacter pylori eradication. J Gastroenterol 2016; 51: 548–559.
33.
Meng WP, Wang ZQ, Deng JQ, Liu Y, Deng MM, Lü MH: The role of H. pylori CagA in regulating hormones of functional dyspepsia patients. Gastroenterol Res Pract 2016; 2016: 7150959.
34.
Hiroi S, Sugano K, Tanaka S, Kawakami K: Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. BMJ Open 2017; 7:e015855.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.